News stories about Mazor Robotics (NASDAQ:MZOR) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mazor Robotics earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 44.8179862733384 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Where Relative Volume Stands?: Mazor Robotics Ltd (NASDAQ: MZOR) – Alpha Beta Stock (alphabetastock.com)
- Mazor Robotics Ltd (NASDAQ: MZOR) – Early Moves to Watch – Alpha Beta Stock (alphabetastock.com)
- Hot Stock under Review – Mazor Robotics Ltd., (NASDAQ: MZOR) – Stock Watch (stocksnewstimes.com)
- ETFs with exposure to Mazor Robotics Ltd. : October 26, 2017 (finance.yahoo.com)
- Mazor Robotics Ltd. (MZOR) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
Shares of Mazor Robotics (NASDAQ MZOR) opened at 58.98 on Monday. The firm’s market cap is $1.42 billion. The firm has a 50 day moving average price of $50.61 and a 200 day moving average price of $41.28. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $59.90.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.09. The company had revenue of $15.46 million for the quarter, compared to analysts’ expectations of $15.38 million. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The business’s revenue was up 86.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.09) EPS. Analysts anticipate that Mazor Robotics will post ($0.77) EPS for the current year.
Several analysts have issued reports on the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $67.00 price target on shares of Mazor Robotics in a research note on Monday. Zacks Investment Research raised Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price target on the stock in a research note on Tuesday, August 15th. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a research note on Thursday, July 6th. Finally, Barclays PLC reissued a “hold” rating and issued a $34.00 price target on shares of Mazor Robotics in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $39.83.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
What are top analysts saying about Mazor Robotics Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mazor Robotics Ltd. and related companies.